lomibuvir

an antiviral agent with polymerase NS5 inhibitory activity

Also Known As:

5-(3,3-dimethylbut-1-ynyl)-3-((trans-4-hydroxycyclohexyl)((trans-4-methylcyclohexyl)carbonyl)amino)thiophene-2-carboxylic acid; VCH-222; VX-222

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Mohamed, Kawthar: 1 article (01/2021)
2.	Rezaei, Nima: 1 article (01/2021)
3.	Saghazadeh, Amene: 1 article (01/2021)
4.	Yazdanpanah, Niloufar: 1 article (01/2021)
5.	Alves, Katia: 1 article (07/2014)
6.	Asmal, Mohammed: 1 article (07/2014)
7.	DeSouza, Cynthia: 1 article (07/2014)
8.	Di Bisceglie, Adrian M: 1 article (07/2014)
9.	Gane, Ed: 1 article (07/2014)
10.	George, Shelley: 1 article (07/2014)

Related Diseases

1.	Infections 07/01/2014 - "VX-222, a non-nucleoside NS5B polymerase inhibitor, in telaprevir-based regimens for genotype 1 hepatitis C virus infection."
2.	Hepatitis C 06/15/2014 - "The direct-acting antivirals (DAAs) currently in development for treatment of hepatitis C fall into four categories: (i) NS3/4A protease inhibitors: ABT-450/r, faldaprevir, asunaprevir, GS-9256, vedroprevir (GS-9451), danoprevir, MK-5172, vaniprevir, sovaprevir, ACH-2684, narlaprevir and simeprevir, in addition to those that are already developed [telaprevir (Incivek®) and boceprevir (Victrelis®)], (ii) NS5A protein inhibitors: ABT-267, daclatasvir, ledipasvir, ACH-2928, ACH-3102, PPI-668, AZD-7295, MK-8742, and GSK 2336805; (iii) NS5B (nucleoside-type) polymerase inhibitors: sofosbuvir (now approved by the FDA since 6 December 2013), GS-0938, mericitabine, VX-135, ALS 2158 and TMC 649128; (iv) NS5B (non-nucleoside-type) polymerase inhibitors: VX-222, ABT-072, ABT-333, deleobuvir, tegobuvir, setrobuvir, VCH-916, VCH-759, BMS-791325 and TMC-647055. "
3.	Acquired Immunodeficiency Syndrome (AIDS) 01/01/2021 - "The review revealed the best-documented multi-target drugs repurposed by computational methods for COVID-19 therapy as follows: antiviral drugs commonly used to treat AIDS/HIV (Atazanavir, Efavirenz, and Dolutegravir Ritonavir, Raltegravir, and Darunavir, Lopinavir, Saquinavir, Nelfinavir, and Indinavir), HCV (Grazoprevir, Lomibuvir, Asunaprevir, Ribavirin, and Simeprevir), HBV (Entecavir), HSV (Penciclovir), CMV (Ganciclovir), and Ebola (Remdesivir), anticoagulant drug (Dabigatran), and an antifungal drug (Itraconazole). "
4.	COVID-19 01/01/2021 - "The review revealed the best-documented multi-target drugs repurposed by computational methods for COVID-19 therapy as follows: antiviral drugs commonly used to treat AIDS/HIV (Atazanavir, Efavirenz, and Dolutegravir Ritonavir, Raltegravir, and Darunavir, Lopinavir, Saquinavir, Nelfinavir, and Indinavir), HCV (Grazoprevir, Lomibuvir, Asunaprevir, Ribavirin, and Simeprevir), HBV (Entecavir), HSV (Penciclovir), CMV (Ganciclovir), and Ebola (Remdesivir), anticoagulant drug (Dabigatran), and an antifungal drug (Itraconazole). "

Related Drugs and Biologics

1.	Nucleosides
2.	Antiviral Agents (Antivirals)
3.	Simeprevir
4.	grazoprevir
5.	asunaprevir
6.	telaprevir
7.	Lopinavir
8.	Nelfinavir (Viracept)
9.	Indinavir (Crixivan)
10.	Ritonavir (Norvir)

Related Therapies and Procedures

1.	Therapeutics